



Schweizerische Pädiatrische Onkologie Gruppe
Groupe d'Oncologie Pédiatrique Suisse
Gruppo d'Oncologia Pediatrica Svizzera
Swiss Paediatric Oncology Group

Pediatric Relapsed AML 2010/01

Acute myeloid leukaemia (AML) is a cancer of the hematopoietic (blood forming) system. It leads to a massive propagation of immature blood cells in the bone marrow. Refractory or relapsed AML is a rare disease with a bad prognosis. Despite improvements in treatment, currently still about 65% of patients with refractory or relapsed AML die from the disease. The Pediatric Relapsed AML 2010/01 study included patients with refractory or relapsed AML. Patients had to be below the age of 18 years at the onset of chemotherapy and below the age of 21 years when treatment of the relapsed or refractory AML begun. The Gesellschaft für Pädiatrische Onkologie und Hämatologie gGmbH in Germany is responsible for the international implementation of the study (sponsor). In Switzerland, the Swiss Paediatric Oncology Group (SPOG) is responsible for the conduct of the study (sponsor representative).

The Pediatric Relapsed AML 2010/01 study tested a new kind of medicine called Mylotarg. The innovative idea behind Mylotarg is to link an antitumor medicine with an antibody that recognizes tumor cells in 90% of AML patients. Scientists hope, that tumour cells will be attacked directly with this new medicine, which would reduce side effects. Mylotarg was given in combination with the current standard therapy of Fludarabine, Daunorubicin and Cytarabine. Half of the patients received Mylotarg before the standard therapy, whereas the other half did not receive Mylotarg. This way, researchers will determine, whether adding Mylotarg to the standard therapy benefits patients with relapsed or refractory AML. The Pediatric Relapsed AML 2010/01 study is terminated in Switzerland. The results of this study are being evaluated.

Contact details for the sponsor representative in Switzerland:

Partner Relations
SPOG Coordinating Center
Effingerstrasse 33
3008 Bern
Phone: +41 31 389 91 89